Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2026)

Crinetics Pharmaceuticals has reported Cash from Financing Activities for 10 years, with the latest figure at $389.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 8686.91% year-over-year to $389.9 million; the trailing twelve-month figure through Mar 2026 stood at $426.0 million (down 31.89% YoY), and the FY2025 full-year result was $40.6 million, down 96.0% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $389.9 million, up from $26.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $556.2 million in Q4 2024, with the low at $115000.0 in Q4 2022.
• Average Cash from Financing Activities over 5 years is $115.2 million, with a median of $12.7 million recorded in 2023.
• Year-over-year, Cash from Financing Activities sank 99.93% in 2022 and jumped 81216.94% in 2024.
• Tracing CRNX's Cash from Financing Activities over 5 years: stood at $115000.0 in 2022, then soared by 34870.43% to $40.2 million in 2023, then jumped by 1283.12% to $556.2 million in 2024, then sank by 95.32% to $26.0 million in 2025, then jumped by 1397.5% to $389.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $389.9 million (Q1 2026), $26.0 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.

Peer Comparison